JAAD:儿童早期肥胖与儿童晚期和青春期特应性皮炎的关系

2021-11-17 医路坦克 MedSci原创

特应性皮炎(AD)是一种常见的儿童慢性病,了解可控制的危险因素对于开发有效的干预措施来预防和治疗AD非常重要。

   

     特应性皮炎(AD)是一种常见的儿童慢性病,了解可控制的危险因素对于开发有效的干预措施来预防和治疗AD非常重要。先前的研究发现,关于儿童时期肥胖与AD之间的关联,结果好坏参半。该文调查了超重(≥85体重指数-百分位数)或肥胖(≥95体重指数-百分位数)与5岁、9岁和15岁AD的关系;5岁超重或肥胖与9岁或15岁AD发展的关系;AD在5岁时出现,超重或肥胖在9岁或15岁时发展。

    该研究人群为出生在美国20个大城市的4898名儿童组成。AD是通过对“过去12个月,(孩子)有湿疹或皮肤过敏吗?”的回应来确定的。在5年,9年和15年的随访调查中进行评估。在5年,9年和15年的家访中评估了体重(以磅为单位)和身高(使用测距仪以厘米为单位)。BMI通过(体重[kg])/(身高[m])计算。

    使用SAS 9.4.3(SAS Institute,Cary,NC)完成统计分析。Logistic回归模型评估了超重/肥胖或肥胖(二元自变量)与儿童AD(二元因变量)之间的关联,以及5岁AD(二元自变量)与童年时期超重/肥胖或肥胖(二元因变量)之间的关联。根据性别和种族/民族进行调整的多变量模型。报告了粗略和调整后的优势比[OR]和95%可信区间[CI]。采用Benjamini-Hochberg方法对多项相依试验进行校正。

    总体而言,在评估的所有儿童年龄中,超重/肥胖或肥胖与AD相关(肥胖的粗略OR[95%CI]:1.25[1.03-1.51],超重/肥胖:1.22[1.02-1.50])。此外,5岁时肥胖和/或超重(在没有AD的人群中)与9岁或15岁时的AD有关(超重/肥胖的调整OR[95%CI]:1.37[1.04-1.79];肥胖症:1.42[1.02-1.99])。5岁的AD(在正常体重的人群中)与9岁或15岁的超重或肥胖无关(超重/肥胖的调整OR[95%CI]:1.10[0.84-1.43];肥胖症:1.18[0.88-1.58])。

    总而言之,儿童早期超重和肥胖与儿童后期的AD相关。然而,儿童早期的AD与儿童后期或青春期的超重/肥胖无关。超重/肥胖可能会增加脂肪组织中脂肪因子的释放,导致可能促进AD的促炎效应。脂联素与低水平的AD有关。这项研究没有评估AD的严重程度,患有皮肤过敏而没有AD的儿童可能已被归类为AD。有必要进行更多的研究,以确定超重/肥胖与AD的关联方向,并确定其原因机制。

 

文献来源:Manjunath J,Silverberg JI,Association of obesity in early childhood with atopic dermatitis in late childhood and adolescence.J Am Acad Dermatol 2021 Sep 03; 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1071277, encodeId=a1a710e12779a, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:47 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071261, encodeId=ed0810e1261f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88b3070708, createdName=849268107, createdTime=Thu Nov 18 07:06:19 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071158, encodeId=7a2710e115886, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Wed Nov 17 17:16:14 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275570, encodeId=ee6812e55701a, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 15 10:43:38 CST 2021, time=2021-11-15, status=1, ipAttribution=)]
    2021-11-18 查查佳佳

    症和危重症病人达到78,740例;全球新

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1071277, encodeId=a1a710e12779a, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:47 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071261, encodeId=ed0810e1261f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88b3070708, createdName=849268107, createdTime=Thu Nov 18 07:06:19 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071158, encodeId=7a2710e115886, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Wed Nov 17 17:16:14 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275570, encodeId=ee6812e55701a, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 15 10:43:38 CST 2021, time=2021-11-15, status=1, ipAttribution=)]
    2021-11-18 849268107

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1071277, encodeId=a1a710e12779a, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:47 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071261, encodeId=ed0810e1261f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88b3070708, createdName=849268107, createdTime=Thu Nov 18 07:06:19 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071158, encodeId=7a2710e115886, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Wed Nov 17 17:16:14 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275570, encodeId=ee6812e55701a, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 15 10:43:38 CST 2021, time=2021-11-15, status=1, ipAttribution=)]
    2021-11-17 MYR哈哈哈哈

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1071277, encodeId=a1a710e12779a, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:47 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071261, encodeId=ed0810e1261f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88b3070708, createdName=849268107, createdTime=Thu Nov 18 07:06:19 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071158, encodeId=7a2710e115886, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73be5472067, createdName=MYR哈哈哈哈, createdTime=Wed Nov 17 17:16:14 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275570, encodeId=ee6812e55701a, content=<a href='/topic/show?id=5d0299032b9' target=_blank style='color:#2F92EE;'>#青春期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99032, encryptionId=5d0299032b9, topicName=青春期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Nov 15 10:43:38 CST 2021, time=2021-11-15, status=1, ipAttribution=)]

相关资讯

J Invest Dermatol:银屑病和特应性皮炎的自噬受损:新的治疗靶点?

自噬是一个重要的生物学过程,它涉及细胞内质量控制、新陈代谢和细胞存活,使细胞能够在应激条件下回收胞质物质。

Abrocitinib获得CHMP的积极意见,用于治疗成人中重度特应性皮炎

辉瑞公司今天宣布,欧洲药品管理局 (EMA) 人用药品委员会 (CHMP) 已采纳了一项积极意见,推荐100毫克和 200毫克剂量的Abrocitinib用于治疗成人中度至重度特应性皮炎。

AJCD:阿布罗西尼治疗中重度特应性皮炎的综合安全性研究

该文是首次报道阿克罗替尼治疗中重度AD患者的长期安全性。阿克罗替尼在患者和剂量选择得当的情况下,具有可控的耐受性和适合长期使用的长期安全性。

靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘,中国II期临床试验已经启动

制药公司Akeso宣布,其候选药物抗IL-4R单克隆抗体(AK120)已经获得中国国家药品监督管理局药品审评中心(CDE)的批准,以在中国启动治疗中重度哮喘的II 期临床试验。

Clin Pharmacol Ther:有针对性地利用安慰剂效应可有效减少特应性皮炎患者的瘙痒

"公开给药"优于"隐藏给药"。在一项随机对照试验中,研究人员旨在表明,专门产生的有针对性的安慰剂效应可以明显增加某一种药物(迪米特里)的作用,应该在临床实践中使用。

Dermatology:JAK抑制剂是治疗特应性皮炎的一种安全且有效的疗法

目前对特应性皮炎(AD)的治疗选择是有限的。有研究提出,JAK抑制剂或是治疗AD的有效药物。近日,发表于Dermatology的一项荟萃分析评估了JAK抑制剂治疗AD的有效性和安全性。